Spots Global Cancer Trial Database for Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Official Title: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Study ID: NCT04703244

Conditions

Breast Cancer

Residual

Interventions

chemotherapy or endocrine therapy for breast cancer

Study Description

Brief Summary: Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Detailed Description: This study is being done to collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed. We will use the blood and tissue for future studies. These studies will try to find ways to treat future breast cancer patients. Because there is cancer left in your body after breast cancer treatment is finished, we think the cancer may be different than other cancers. Tissue from surgery will be used to try to grow that kind of cancer in the lab so we can find out more about it and how to treat it. Blood samples will be used to look at measurements of biomarkers to see how this cancer is different and seek new ways to identify and treat it.